Pegbelfermin in Patients With Nonalcoholic Steatohepatitis and Compensated Cirrhosis (FALCON 2): A Randomized Phase 2b Study
Clinical Gastroenterology and Hepatology · 2024-01 · 22 (1) · 113-123.e9
DOI: 10.1016/j.cgh.2023.04.012 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Gastroenterology and Hepatology, 2024-01. Verfasst von Manal F Abdelmalek und 19 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease. Die Arbeit wurde bisher 106-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Bristol-Myers Squibb Co Summit, Bristol-Myers Squibb.
Abstract (Originalsprache)
BACKGROUND & AIMS: Pegbelfermin is a polyethylene glycol-conjugated analog of human fibroblast growth factor 21, a nonmitogenic hormone that regulates energy metabolism. This phase 2b study evaluated 48-week pegbelfermin treatment in patients with nonalcoholic steatohepatitis (NASH) with compensated cirrhosis. METHODS: FALCON 2 (NCT03486912) was a randomized (1:1:1:1), double-blind, placebo-controlled study. Eligible adults had biopsy-confirmed NASH and stage 4 fibrosis. Pegbelfermin (10, 20, or 40 mg) or placebo was injected subcutaneously once weekly. The primary endpoint was 1 or more stages of improvement in the NASH Clinical Research Network fibrosis score without NASH worsening at week 48; pegbelfermin dose response was assessed using a Cochran-Armitage trend test across proportions (1-sided α = .05). Additional endpoints included histologic and noninvasive measures of steatosis, fibrosis, and liver injury/inflammation. RESULTS: Overall, 155 patients were randomized, and 154 patients received treatment. At week 48, 24% to 28% of the pegbelfermin arms had primary endpoint responses vs 31% of the placebo arm (P = .361). Nonalcoholic fatty liver disease activity score improvements were more frequent with pegbelfermin vs placebo and were driven primarily by reduced lobular inflammation. Numerically higher proportions of the pegbelfermin arms had liver stiffness (magnetic resonance elastography) and steatosis (magnetic resonance imaging-proton density fat fraction) improvements vs placebo; these differences were not statistically significant. Mean N-terminal type III collagen propeptide, alanine aminotransferase, and aspartate aminotransferase values were numerically lower in the 20- and/or 40-mg pegbelfermin arms compared with placebo. Serious adverse events were more frequent with pegbelfermin vs placebo, although none were treatment related. One patient (40-mg pegbelfermin) discontinued treatment because of a treatment-emergent adverse event (worsening ascites). CONCLUSIONS: FALCON 2 did not meet its primary endpoint of 1 or more stages of improvement in the NASH Clinical Research Network fibrosis without NASH worsening assessed via biopsy. Pegbelfermin generally was well tolerated in this advanced NASH population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota.
- Department of Internal Medicine, Virginia Commonwealth University, Richmond, Virginia.
- Department of Gastroenterology and Hepatology, Yokohama City University, Yokohama, Japan.
- Department of Internal Medicine, Saint Louis University, St. Louis, Missouri.
- Center for Liver Diseases, Inova Fairfax Hospital, Falls Church, Virginia.
- The Texas Liver Institute, University of Texas San Antonio, San Antonio, Texas.
Förderung
- Bristol-Myers Squibb Co Summit
- Bristol-Myers Squibb
Zitieren
APA
Abdelmalek, M. F., Sanyal, A. J., Nakajima, A., Neuschwander-Tetri, B. A., Goodman, Z. D., Lawitz, E. J., Harrison, S. A., Jacobson, I. M., Imajo, K., Gunn, N., Halegoua-DeMarzio, D., Akahane, T., Boone, B., Yamaguchi, M., Chatterjee, A., Tirucherai, G. S., Shevell, D. E., Du, S., Charles, E. D., & Loomba, R. (2024). Pegbelfermin in Patients With Nonalcoholic Steatohepatitis and Compensated Cirrhosis (FALCON 2): A Randomized Phase 2b Study. Clinical Gastroenterology and Hepatology, 22(1), 113-123.e9. https://doi.org/10.1016/j.cgh.2023.04.012
Vancouver
Abdelmalek MF, Sanyal AJ, Nakajima A, Neuschwander-Tetri BA, Goodman ZD, Lawitz EJ, et al. Pegbelfermin in Patients With Nonalcoholic Steatohepatitis and Compensated Cirrhosis (FALCON 2): A Randomized Phase 2b Study. Clinical Gastroenterology and Hepatology. 2024;22(1):113-123.e9. doi:10.1016/j.cgh.2023.04.012
BibTeX
@article{Abdelmalek2024,
author = {Abdelmalek, Manal F and Sanyal, Arun J and Nakajima, Atsushi and Neuschwander-Tetri, Brent A and Goodman, Zachary D and Lawitz, Eric J and Harrison, Stephen A and Jacobson, Ira M and Imajo, Kento and Gunn, Nadege and Halegoua-DeMarzio, Dina and Akahane, Takemi and Boone, Bradly and Yamaguchi, Masayuki and Chatterjee, Arkendu and Tirucherai, Giridhar S and Shevell, Diane E and Du, Shuyan and Charles, Edgar D and Loomba, Rohit},
title = {Pegbelfermin in Patients With Nonalcoholic Steatohepatitis and Compensated Cirrhosis (FALCON 2): A Randomized Phase 2b Study},
journal = {Clinical Gastroenterology and Hepatology},
year = {2024},
volume = {22},
number = {1},
pages = {113--123.e9},
doi = {10.1016/j.cgh.2023.04.012}
}
EUVIMED